Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Life Science Alliance|November 14, 2022
LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of SlugValentina Cutano, Jessica Marianne Ferreira Mendes, Sara Escudeiro-Lopes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2024
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC StudyNiels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2026
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancerNatalie I Vokes, Jessica L Symons, Brooke Rhead, et al.
JTO Clinical and Research Reports|October 10, 2025
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER StudyByoung Chul Cho, Myung-Ju Ahn, Makoto Nishio, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Profiling extracellular vesicles in circulation enables the early detection of ovarian cancerAla Jo, Allen Green, Jamie E Medina, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 24, 2023
Inaugurating High-Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer DetectionAla Jo, Allen Green, Jamie E Medina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
Gynecologic Oncology|February 14, 2026
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trialShannon N Westin, Kathleen Moore, Hye Sook Chon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLCNatalie I Vokes, Ana Galan Cobo, Margarita Fernandez-Chas, et al.
Cancer Discovery|November 7, 2020
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination ImmunotherapySonia Iyer, Shuang Zhang, Simge Yucel, et al.
Pageof 3